Acetyl-L-Carnitine
Osteoarthritis
Khyber Medical University PeshawarN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Osteoarthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Buprenorphine Mundipharma Pte Ltd. | Phase 4 | BBB |
Naltrexone Brigham and Women's Hospital | Phase 4 | BBB |
FENTANYL Janssen Pharmaceutica | Phase 4 | BBB |
Oxycodone Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BBB |
Liraglutide Henrik Gudbergsen | Phase 4 | BBB |
View all 47 →
Same molecule, other indications
Acetyl-L-Carnitine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →